You are here

Target Validation and Disease Positioning

We place great value on close interactions with expert academic biologists and consult closely with originating PIs and their laboratories during the target validation phase, which is undertaken collaboratively and transparently. In the majority of cases, these studies involve confirmation and expansion of key biological data including experimental evaluation of phenotypic effects and identification of potential pharmacodynamic (PD) biomarkers. Early identification of PD biomarkers is critical in understanding target modulation and for the development of a drug discovery cascade. Validation within themed areas allows us to assess multiple targets as part of a single work plan, mitigate portfolio risk and enable decisions on which targets to progress.